Navigation Links
New Study Shows PCR and FCR Have Significant Activity in B-cell Chronic Lymphocytic Leukemia
Date:12/8/2008

US Oncology Affiliated Physicians Participate in ASH Conference

SAN FRANCISCO, Dec. 8 /PRNewswire/ -- A leading cancer researcher affiliated with the US Oncology Research Network will present findings from a randomized, multicenter Phase III trial that compared FCR and PCR in patients with B-cell chronic lymphocytic leukemia (CLL).

The study results will be given in an oral presentation by Dr. Craig Reynolds of Ocala Oncology Center at the 50th Annual Meeting of the American Society of Hematology (ASH) held December 6-9, 2008 in San Francisco. Dr. Reynolds is the lead investigator and serves as co-chairman, and chairman for new protocol development, of US Oncology's National Lung Cancer Research Committee.

Purine analog-based regimens have emerged as highly active regimens in the treatment of chronic lymphocytic lymphoma (CLL). Promising results have been reported with the combination of fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) by Keating and colleagues at the University of Texas M.D. Anderson Cancer Center. Previous US Oncology Research Network, as well as a Mayo Clinic and MSKCC trials, evaluated the combination of pentostatin (P), cyclophosphamide (C), and rituximab (R) (PCR); results suggested similar efficacy with less infectious complications than that seen with FCR.

The current multicenter, randomized, community-based trial was conducted to compare FCR and PCR in previously untreated or minimally treated B-cell chronic lymphocytic leukemia. The primary end point of the study was infectious complications with efficacy and safety as secondary endpoints. Correlative studies of immune function were conducted by Kay and colleagues at the Mayo Clinic and will be reported separately.

"This study establishes the role of these regimens in the treatment of CCL," said Dr. Reynolds. "New therapies such as these offer hope for our
'/>"/>

SOURCE US Oncology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
2. Neuronetrix Announces Preliminary Alzheimers Study Results at the Society for Neuroscience Conference
3. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
4. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
5. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
6. Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion
7. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
8. Positive Phase II Study of Paciras EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
9. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
10. Gene Therapy Corrects Sickle Cell Disease in Laboratory Study
11. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... --NOWDiagnostics Inc., based in Springdale, Ark. , ... Canada , a move that brings the company ... have greater access to information concerning their health. ... blood-based rapid tests that allow health care providers to ... ailments and diseases. ZBx Corporation, a Toronto ...
(Date:9/1/2015)... , Sept. 1, 2015  Dr. Cindy ... Labs , the cannabis testing subsidiary of DigiPath, Inc. ... Group about the lack of consistency in today,s ... online resource for medical cannabis information, she explained that ... because their lack of uniform requirements makes standardization impossible. ...
(Date:9/1/2015)... 1, 2015   Alpha Imaging LLC , a leading distributor ... announced today that they have been awarded exclusive rights to ... in Michigan.   The new territory supplements Alpha Imaging,s existing Shimadzu sales ... Ohio , Indiana , ... , West Virginia , Delaware ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3Alpha Imaging Expands Shimadzu Territory 2
... Medical Systems (NYSE: VAR ) today announced that ... N.A. to repurchase $250 million of its common stock under ... revolving credit facility with Bank of America, N.A. to increase ... Under the accelerated repurchase agreement, Varian will pay $250 ...
... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced ... trial evaluating the safety and pharmacokinetics of dabigatran ... valves.(1) The 12-week study will compare three doses ... 300mg bid) to warfarin in patients with both ...
Cached Medicine Technology:Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 2Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 4Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 5Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 6Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 7
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... According to ... Association, individuals with type 2 diabetes that participated in a three year study about ... years down the line if they elected weight loss surgery at the onset of ...
(Date:9/1/2015)... PALMYRA, Wis. (PRWEB) , ... September 01, 2015 ... ... every person differently. If not managed, stress created from everyday life changes can ... and tonic herbs that provide support for coping with stress. Herbal supplement manufacturer ...
(Date:9/1/2015)... ... September 01, 2015 , ... Philanthropic giving in the U.S. ... issues and needs. Money for Good 2015, released today by Camber Collective, goes to ... annual potential to mobilize up to $22B in new philanthropic giving and shift $25B ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... cure and prevent different malignancies. Some options for cancer treatment are available ... to which distinctive approach is necessary for effective treatment. Several molecules have ...
(Date:9/1/2015)... ... 01, 2015 , ... Splashtop Inc. , the worldwide ... , a solution optimized for MSPs and IT professionals looking for a cost ... inadequate customer services of existing remote support solution, many MSPs and ITs have ...
Breaking Medicine News(10 mins):Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 2Health News:MediHerb Launches New Herbal Supplement to Help with the Challenges of Everyday Life 3Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 2Health News:Camber Collective Releases Money for Good 2015 - Revealing Root Causes to Why Charitable Giving Has Been Stuck at 2% GDP Since the 70s 3Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 2Health News:CD Antigen Cancer Market and Pipeline Landscape Examined in Comprehensive Kuick Research Report Published at MarketPublishers.com 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 2Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 3Health News:Splashtop Launches Splashtop Business for Remote Support, the Simple, Reliable, and Cost-Effective Solution for MSPs and IT Professionals 4
... March 15, 2011Since the first laparoscopic procedure was performed ... Washington University in St. Louis, this breakthrough minimally invasive ... nephrectomy. This remarkable achievement is celebrated with a series ... a peer-reviewed journal published by Mary Ann Liebert, Inc. ...
... are not successfully treated for depression are at higher risk ... to a study in the March 15, 2011 issue of ... as a third of those who experience a stroke develop ... the schools of health and rehabilitation sciences and of medicine ...
... Institutet in Sweden shows, that a specific inflammatory factor ... valve disease aortic stenosis. The results suggest that anti-inflammatory ... stenosis is the most common heart valve disease, which ... the aortic valve. This is typically seen in the ...
... (BCS) results from hepatic venous outflow obstruction,at any ... Few patients respond to,medical treatment (anticoagulation thrombolytic ... restore the hepatic blood flow. Restoring outflow in ... dilatation stenting is the management of choice. ...
... HealthDay Reporter , MONDAY, March 14 (HealthDay News) ... for type 2 diabetes, an older drug -- metformin -- ... analysis of research on diabetes medications. The analysis ... all of them lower blood sugar levels by a similar ...
... home industry is booming in China as a rapid ... a nationwide shift from traditional family care to institutional ... The study, led by Zhanlian Feng, assistant professor ... Journal of the American Geriatrics Society , is the ...
Cached Medicine News:Health News:20th anniversary of first laparoscopic nephrectomy 2Health News:Managing post-stroke depression improves physical functioning 2Health News:Managing post-stroke depression improves physical functioning 3Health News:Inflammation behind heart valve disease 2Health News: Metformin Still Best First-Line Type 2 Diabetes Drug 2Health News: Metformin Still Best First-Line Type 2 Diabetes Drug 3Health News:Nursing home boom in China has little government involvement 2Health News:Nursing home boom in China has little government involvement 3
... a whole blood hematology control manufactured specifically ... 120, and the Coulter AcT5diff instruments. The ... white cell differential, positioning the populations within ... systems. The product offers 105-day closed-vial stability ...
... assayed hematology control, offers complete assay values ... with the Coulter GENS, STKS, MAXM and ... stability, 105-day closed-vial stability and is available ... 4.0ml pierceable cap vial is compatible with ...
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
Medicine Products: